| Q39014987 | Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis. |
| Q35293000 | Amyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron |
| Q34566679 | Amyotrophic lateral sclerosis: objective upper motor neuron markers |
| Q64079969 | Biomarkers in Motor Neuron Disease: A State of the Art Review |
| Q37523903 | Biomarkers in amyotrophic lateral sclerosis: facts and future horizons |
| Q53191097 | Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. |
| Q53397742 | Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. |
| Q92255300 | Diffusion kurtosis and quantitative susceptibility mapping MRI are sensitive to structural abnormalities in amyotrophic lateral sclerosis |
| Q41860558 | EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases |
| Q35800499 | Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q52920769 | Flow-metabolism uncoupling in the cervical spinal cord of ALS patients. |
| Q30664229 | Imaging and neurochemical markers for diagnosis and disease progression in ALS. |
| Q33734082 | Inter-relation between "classic" motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study |
| Q48587226 | MRI and SPECT findings in amyotrophic lateral sclerosis. Demonstration of upper motor neurone involvement by clinical neuroimaging |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q41949133 | Metabolic Stress and Disorders Related to Alterations in Mitochondrial Fission or Fusion |
| Q37466059 | Mitochondria: a therapeutic target in neurodegeneration |
| Q37348590 | Mitochondrial approaches for neuroprotection |
| Q55981632 | Mitochondrial dysfunction in neurodegenerative diseases |
| Q83316027 | Neuroimaging in amyotrophic lateral sclerosis |
| Q30873214 | Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes |
| Q30832443 | Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis |
| Q49334640 | Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease. |
| Q62785679 | Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q36489599 | PET: its clinical role in neurology |
| Q48367540 | Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients |
| Q34429131 | Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study |
| Q64076813 | Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis |
| Q33735560 | Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis |
| Q45977937 | Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis |
| Q47142121 | Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: A fluoro-deoxyglucose positron emission tomography study |
| Q39042842 | Role of PET and SPECT in the study of amyotrophic lateral sclerosis. |
| Q38577066 | The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. |
| Q34152927 | Treatment of amyotrophic lateral sclerosis--what is the next step? |
| Q36114275 | Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis |